Silverberg Bernstein Capital Management LLC Boosts Stake in Pfizer Inc. $PFE

Silverberg Bernstein Capital Management LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 41.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,850 shares of the biopharmaceutical company’s stock after purchasing an additional 4,050 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pfizer were worth $336,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bessemer Group Inc. increased its stake in Pfizer by 11.1% in the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock worth $3,358,000 after buying an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK increased its stake in Pfizer by 1.2% in the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock worth $35,817,000 after buying an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp purchased a new stake in Pfizer in the 1st quarter worth $8,283,000. Westbourne Investments Inc. purchased a new stake in Pfizer in the 1st quarter worth $2,411,000. Finally, Strs Ohio purchased a new stake in Pfizer in the 1st quarter worth $49,968,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Up 0.5%

NYSE:PFE opened at $23.98 on Tuesday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The firm has a fifty day simple moving average of $24.76 and a 200-day simple moving average of $24.25. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $136.34 billion, a P/E ratio of 12.76, a PEG ratio of 0.85 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the firm posted $0.60 earnings per share. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer’s payout ratio is presently 91.49%.

Wall Street Analysts Forecast Growth

Several research firms have commented on PFE. Morgan Stanley increased their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. HSBC dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a report on Monday, May 19th. Jefferies Financial Group increased their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, May 21st. Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Bank of America increased their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.